AI's Role in Biomarker Discovery: Insights from Recent Review
A new review highlights the potential of AI in enhancing biomarker discovery and clinical application across various diseases.
AI can integrate diverse data types for effective biomarker identification.
Challenges such as data bias and reproducibility remain critical in biomarker validation.
Future developments require interdisciplinary collaboration and standardized evaluation methods.
A recent review published in the journal Signal Transduction and Targeted Therapy explores the significant role of artificial intelligence (AI) in the discovery and validation of biomarkers across various diseases. The authors emphasize that while biomarkers are essential for detecting and guiding treatment for health issues, many candidates fail to demonstrate reproducibility in independent studies, which limits their clinical utility.
The review outlines that effective biomarkers must possess strong predictive capabilities and be biologically relevant. AI's ability to analyze and integrate diverse data types—ranging from genomic and proteomic to imaging and digital data—can help identify complex patterns that are crucial for biomarker development. However, the authors caution that issues such as data bias, confounding factors, and weak external validation can hinder the translation of AI findings into clinical practice.
Among the various types of biomarkers discussed, the review highlights molecular, cellular, imaging, and digital biomarkers. It notes that while circulating biomarkers offer a minimally invasive way to assess disease, their effectiveness is influenced by factors such as preanalytical processing and patient characteristics. The review also emphasizes the importance of imaging biomarkers and digital data from wearable devices in capturing health metrics, although challenges like device variability and data completeness persist.
Looking at the broader implications, the authors argue that AI can significantly enhance the biomarker discovery process, but it must be accompanied by rigorous validation and testing. The review calls for a comprehensive development pathway that includes external validation across diverse cohorts and emphasizes the need for transparent reporting and standardized assessment of biomarkers. This approach is vital for ensuring that AI-derived biomarkers translate effectively into clinical applications.
In conclusion, while AI holds great promise for advancing biomarker discovery, the review stresses that achieving clinical value requires reproducibility, independent testing, and evidence of improved patient outcomes. The authors advocate for interdisciplinary collaboration and harmonized data collection to facilitate the transition of AI-derived biomarkers from research to practical therapeutic applications.
